Boehringer Ingelheim and Saniona collaborate on schizophrenia research

Boehringer Ingelheim has announced a new collaboration with Saniona that will focus on innovative research in the field of schizophrenia.

Saniona, a leading biotech company with expertise in ion channel drug discovery, will be seeking to discover and develop novel compounds that could potentially help to restore brain network activity among schizophrenia patients.

Under the terms of the deal, Saniona may receive up to 90 million euros (76.86 million pounds) in milestone payments, including an upfront fee of five million euros, as well as royalties on worldwide net sales of any products resulting from the collaboration.

Boehringer Ingelheim, meanwhile, will gain exclusive worldwide rights to research, develop, manufacture and commercialise these medicines.

Dr Clive Wood, senior corporate vice-president for discovery research at Boehringer Ingelheim, said: "Working together and blending our joint expertise and capabilities, we have the potential to advance new treatment options for schizophrenia."

This aligns with Boehringer Ingelheim's current drug discovery strategy for neuropsychiatric diseases, which focuses on investigating dominant symptom domains and their underlying neurobiology across a range of mental disorders.

With? ?over? ?20? ?years? ?of? ?experience? ?within? ?the? ?pharmaceutical? ?market,? ?we? ?at? ?Zenopa? ?have? ?the knowledge,? ?skills? ?and? ?expertise? ?to? ?help? ?find? ?the? ?right? ?job? ?for? ?you.? ?To? ?find? ?out? ?more? ?about? ?the current? ?pharmaceutical? ?roles? ?we? ?have? ?available,? ?you? ?can? ?search? ?for? ?the? ?latest? ?job? ?roles, register? ?your? ?details,? ?or? ?contact? ?the? ?team? ?today.